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medications and raloxifene in the treatment of osteo-
porosis. METHODS: Data from a large health insurer
were used to identify 59,902 osteoporosis patients who
initiated drug therapy between January 1, 1998 and
August 30, 2000. Multivariate statistical models were
developed for duration of therapy, uninterrupted therapy
over one year, time to discontinuation, time to a change
in therapy and health care costs over one year. Separate
models were estimated for the effect of drug use patterns
(compliance, switching) and initial drug therapy (ralox-
ifene, bisphosphonates vs. HRT). Other independent
variables included age, gender, type of insurance, history
of fractures, and patient diagnostic and drug proﬁles at
baseline. Sensitivity analyses were conducted to investi-
gate if the impact of alternative drugs varied with age.
RESULTS: Bisphosphonate patients were more compliant
than HRT patients, though compliance rates were below
25% for all drugs. Drug use patterns for raloxifene
patients did not differ signiﬁcantly from HRT patients.
Compliance was correlated with a reduced risk of hip
fractures of 43% (p < 0.05) and lower health care costs
of -$213 (p < 0.01), while switching increased the risk of
hip fractures by 84% (p < 0.05) and increased costs by
$278 (p < 0.01). Bisphosphonate patients were twice as
likely as HRT patients to experience vertebral, Colles and
other fractures and experienced higher health care costs
relative to HRT patients of $510 (p < 0.0001). The 
estimated impacts of raloxifene and bisphosphonates
improve signiﬁcantly with patient age. For example,
raloxifene’s impact on total costs improved from +$314
for patients under 55 to -$570 for patients over 65.
CONCLUSIONS: Compliance with drug therapies for
osteoporosis over a 1-year period is poor (<25%) leaving
patients at risk for fractures and higher health care costs.
Alternatives to HRT were associated with better patient
outcomes, especially for older patients.
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OBJECTIVE: To determine if clinical outcomes and total
medical and drug costs are affected by noncompliance
with alendronate. METHODS: Data was gathered retro-
spectively from an integrated pharmacy and medical
claims database. Patients over the age of 18 years old who
were taking alendronate daily at the beginning of the
accrual period were selected for inclusion. Patients with
a diagnosis of Paget’s disease, renal disease/failure were
excluded. Demographics including mean age, sex, and
concomitant medications and diagnoses were collected.
Medication adherence was calculated by dividing the sum
of days of supply dispensed by the sum of days in all reﬁll
intervals. Percent compliance was broken down into
quintiles and cohort groups. Days on therapy, number
and type of disease sequela, time to ﬁrst disease sequela
event, monthly cost of disease sequela and adverse drug
events, and monthly total medical and drug costs were
calculated for each group. ANOVA or non-parametric
equivalents were used. RESULTS: 13,275 patients (93%
females) were included in this analysis. The mean age 
was 67.3 years and the average number of diagnoses per
patient was 7.9. Ninety-four percent of the study popu-
lation had a diagnosis of osteoporosis. Sixty-six percent
of the patients were >80% compliant. Total costs for the
compliance cohorts were analyzed using the Kruskal-
Wallis test for non-parametric data, and were signiﬁcantly
higher in the =>80% versus the <80% compliant cohort
($725.46 vs $547.03, p < 0.0001). Patients in the =>80%
cohort experienced more disease sequelae, and the
medical costs associated with them were lower but were
not statistically signiﬁcant (p = 0.09). CONCLUSION:
Compliance with alendronate therapy did not positively
affect outcomes with respect to number of disease seque-
lae or their costs. Since bone loss is cumulative, and 
bisphosphonates have been proven to reduce and prevent
fractures, cost savings due to adherence may be realized
at points beyond the initial year of treatment.
ARTHRITIS/OSTEOPOROSIS—Quality of
Life/Preference Based Outcomes
PAR15
INITIAL VALIDATION OF THE WILLINGNESS TO
PAY (WTP) TECHNIQUE FOR MEASURING
HEALTH CARE PREFERENCES IN JUVENILE
IDIOPATHIC ARTHRITIS (JIA)
Brunner HI, Barron A
Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH, USA
WTP estimates are highly tangible and thus suitable 
for measuring health care preferences. The feasibility 
and usefulness of WTP in JIA has not been examined.
OBJECITVE: To assess the feasibility and construct valid-
ity of the WTP for measuring health preferences in JIA.
METHOD: Parents were asked to estimate the monthly
US dollar amount they would be willing to pay to obtain
for their child 1) Drug A that provides near complete
relief of arthritis symptoms (WTP(A)); and 2) Drug B that
eliminates gastrointestinal (GI) symptoms (WTP(B)). A
closed-ended question approach (yes/no) was used 
with random assignment of the initial bids (Drug A:
$50/$125/$200/$300; Drug B: $5/$25/$30/$40). Parents
who agreed to pay the initial bid were then asked whether
they would pay 200% and then 400% of this initial 
bid. Information was obtained regarding family income,
healthcare expenses as well as on various JIA outcomes:
number of involved joints; visual analog scales of pain,
GI discomfort and overall well-being; Childhood Health
Assessment Questionnaire (CHAQ); the Pediatric Quality
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of Life Inventory Rheumatology Module (PedsQL-R) and
Generic Core Scale (PedsQL-G). Spearman correlations
and regression analysis were done to examine the rela-
tionship between the WTP(A) or WTP(B) and other JIA
outcomes. RESULTS: Fifty-four families of children with
JIA (mean age: 10 yrs) were interviewed. Fifty-four
percent of the patients had some GI discomfort and 
the mean/median number of involved joints was 4.3/2.
WTP rating was refused by ﬁve families (9%). The
mean/median of WTP(A) was $323/$200 and $54/$38
for WTP(B), respectively. After adjustment for the
monthly family income, WTP (A) and WTP (B) were
moderately corrrelated to pain, CHAQ, PedsQL-R 
and PedsQL-G (r = 0.35–0.47). CONCLUSIONS: WTP
appears to be a promising, easy to use method for assess-
ing health care preferences in JIA. WTP is feasible and
has construct validity in JIA. Further validation in a larger
group of patients is warranted.
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OBJECTIVE: To quantify GI symptoms of children with
JIA using the Gastrointestinal Symptom Scale for Pedi-
atrics (GIPS), to verify for the GIPS reliability, construct
validity and quality of parent proxy reporting, and to
evaluate the relationship of GI symptoms severity and
HRQL in JIA. METHODS: A convenience sample of 54
families of JIA patients was interviewed twice (patients
(pts) >7 yrs, 1 parent per family). GI symptom severity
was measured by the GIPS (7 item scale with yes/no
answers; score 0 - 7; 0 = no GI symptoms) and a visual
analog scale (VAS-GI). Information on other outcomes
was obtained, incl. the Childhood Health Assessment
Questionnaire (CHAQ); the Pediatric Quality of Life
Inventory Rheumatology Module (PedsQL-R) and
Generic Core Scale (PedsQL-G). RESULTS: Forty-six
percent of the pts (mean age: 10.3 yrs) had some GI symp-
toms. Treatments included NSAIDs (n = 45), methotrex-
ate (MTX; n = 33) and GI protectants (n = 21). Intrarater
reliability and internal consistency of the GIPS (parent
report: weighted kappa = .7; Crohnbachs-á = 1) were
high; the quality of parent proxy reports was very good
(intraclass corr. coeff. = .7). Scores of the GIPS, GI-VAS,
PedsQL-R and PedsQl-G (r = .5-.8) were strongly corre-
lated. The mean GIPS score of pts having GI symptoms
was 2, with nausea and epigastric pain being most
common. Use of MTX (p < .003) and NSAIDs (p < .03)
led to signiﬁcantly higher and GI protectants to signiﬁ-
cantly lower GIPS scores (p < .008) in univariate analy-
sis. Corrected for the disease severity and activity,
children with moderate/severe GI symptoms (GIPS > 2; n
= 16) had signiﬁcantly lower HRQL (PedsQL-R: p < .005;
PedsQL-G: p < .04) and more disability (CHAQ; p <.005)
compared to patients without GI symptoms. CONCLU-
SION: The GIPS is a reliable and valid measure of GI
symptom severity. GI symptoms are frequent among chil-
dren with JIA and, if moderate or severe, have a signiﬁ-
cant negative impact on the HRQL. GI side effects require
special consideration for patient management and med-
ication choices in JIA.
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OBJECTIVES: Summary physical and mental health
scores for the Short Form (SF) measures assume that
physical and mental health are uncorrelated. The Rand
Health Status Inventory (HSI) measures allow correlation
and also employ item weights derived from item-response
theory. Do these different approaches to scoring matter?
The objective was to compare summary scores using both
the SF and Rand HSI. METHODS: SF-36 and the Health
Utilities Index Mark 3 (HUI3) were administered to a
cohort of patients waiting for elective total hip arthro-
plasty (THA). SF-12 and HUI3 were administered to 
a cohort of high-risk primary-care patients. Summary
scores were generated and compared. Single-attribute
utility scores for emotion in HUI3 were also computed.
Canadian and U.S norms for SF, Rand HSI, and HUI3
were used to interpret results. RESULTS: For THA
patients mean physical health scores were 28 and 36 for
SF and Rand HSI. Mean mental health scores were 55
and 42. For the primary-care patients the scores were 34
and 36 for physical and 46 and 40 for mental health.
HUI3 emotion scores for the primary-care patients were
well below population norm. CONCLUSIONS: SF and
Rand HSI provided similar summary scores in the THA
study. However, SF and Rand HSI mental health scores
differed in the primary-care patient cohort and results
from HUI3 corroborate the mental health deﬁcits identi-
ﬁed by the Rand HSI. It may be wise for investigators to
utilize both SF and Rand HSI scoring systems.
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